Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for folic acid
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on folic acid or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on folic acid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Folicacid supplements in pregnancy and severe language delay in children. Prenatal folicacid supplements reduce the risk of neural tube defects and may have beneficial effects on other aspects of neurodevelopment.To examine associations between mothers' use of prenatal folicacid supplements and risk of severe language delay in their children at age 3 years.The prospective observational Norwegian Mother and Child Cohort Study recruited pregnant women between 1999 and December 2008. Data (...) on children born before 2008 whose mothers returned the 3-year follow-up questionnaire by June 16, 2010, were used. Maternal use of folicacid supplements within the interval from 4 weeks before to 8 weeks after conception was the exposure. Relative risks were approximated by estimating odds ratios (ORs) with 95% CIs in a logistic regression analysis.Children's language competency at age 3 years measured by maternal report on a 6-point ordinal language grammar scale. Children with minimal expressive
Homocysteine-Lowering and Cardiovascular Disease Outcomes in Kidney Transplant Recipients: Primary Results From the FolicAcid for Vascular Outcome Reduction in Transplantation Trial Kidney transplant recipients, like other patients with chronic kidney disease, experience excess risk of cardiovascular disease and elevated total homocysteine concentrations. Observational studies of patients with chronic kidney disease suggest increased homocysteine is a risk factor for cardiovascular disease (...) . The impact of lowering total homocysteine levels in kidney transplant recipients is unknown.In a double-blind controlled trial, we randomized 4110 stable kidney transplant recipients to a multivitamin that included either a high dose (n=2056) or low dose (n=2054) of folicacid, vitamin B6, and vitamin B12 to determine whether decreasing total homocysteine concentrations reduced the rate of the primary composite arteriosclerotic cardiovascular disease outcome (myocardial infarction, stroke, cardiovascular
Folicacid for fragile X syndrome. It has been argued that individuals with fragile X syndrome could have low folate levels in their bodies and that supplementing their dietary intake might remediate the adverse developmental and behavioural effects of the condition.To review the efficacy and safety of folicacid in the treatment of people with fragile X syndrome.We searched four databases in November 2010: CENTRAL, PubMed, EMBASE and PsycINFO.Randomised controlled trials.Two review authors (...) design. The duration of follow-up ranged from two months to 12 months and the period on folicacid or placebo ranged from two to eight months. Doses of folicacid ranged from 10 mg to 250 mg per day, 10 mg per day being the most common. Most of the younger patients involved were also taking part in special education programmes (usually involving language and occupational therapy).We were not able to perform meta-analysis to combine results but none of the individual studies found evidence of clinical
Folicacid supplementation prevents phenytoin-induced gingival overgrowth in children Gingival overgrowth is an important adverse effect of phenytoin (PHT) therapy, occurring in about half of the patients. This study aimed to evaluate the effect of oral folicacid supplementation (0.5 mg/day) for the prevention of PHT-induced gingival overgrowth (PIGO) in children with epilepsy aged 6-15 years on PHT monotherapy for 6 months.This was a randomized, double-blind, placebo-controlled trial (...) conducted at a tertiary level hospital from May 2008 to June 2009. Children aged 6-15 years started on PHT monotherapy within last 1 month were eligible for inclusion. Preexisting gingival overgrowth, use of other folicacid antagonists, and macrocytic anemia were exclusion criteria. Trial subjects were randomized to receive either folicacid or placebo. The primary outcome measure was incidence of any degree of gingival overgrowth after 6 months of PHT monotherapy. The trial was registered
Intermittent iron and folicacid supplementation in menstruating women WHO | Intermittent iron and folicacid supplementation in menstruating women WHO Regional websites Access Nutrition Menu Intermittent iron and folicacid supplementation in menstruating women Guideline Authors : World Health Organization Publication details Number of pages : 30 Publication date : 2011 Languages : Chinese, English, Farsi, French, Portuguese, Russian, Spanish ISBN : 978 92 4 150202 3 Downloads pdf, 1.24Mb pdf (...) , 661.67kb pdf, 762.61kb Overview This guideline provides global, evidence-informed, recommendations on the intermittent use of iron and folicacid supplements as a public health measure for the purpose of reducing anaemia and improving iron status among menstruating women. The guideline will help Members States and their partners in their efforts to make informed decisions on the appropriate nutrition actions to achieve the Millennium Development Goals, in particular, promotion of gender equality
Vitamins B(12), B(6), and folicacid for cognition in older men To investigate whether supplementing older men with vitamins B(12), B(6), and folicacid improves cognitive function.The investigators recruited 299 community-representative hypertensive men 75 years and older to a randomized, double-blind controlled clinical trial of folicacid, vitamin B(6), and B(12) supplementation vs placebo over 2 years. The primary outcome of interest was the change in the cognitive subscale (...) , p = 0.478). There was a nonsignificant 28% decrease in the risk of cognitive impairment (odds ratio 0.72, 95% confidence interval 0.25-2.09) and dementia (hazard ratio 0.72, 95% confidence interval 0.29-1.78) over 8 years of follow-up.The daily supplementation of vitamins B(12), B(6), and folicacid does not benefit cognitive function in older men, nor does it reduce the risk of cognitive impairment or dementia.This study provides Class I evidence that vitamin supplementation with daily doses
Mental health literacy, folicacid and vitamin B12, and physical activity for the prevention of depression in older adults: randomised controlled trial Few randomised controlled trials (RCTs) have examined potential preventive agents in high-risk community populations.To determine whether a mental health literacy intervention, the promotion of physical activity, or folicacid plus vitamin B(12) reduce depression symptoms in community-dwelling older adults with elevated psychological distress.An (...) RCT with a completely crossed 2 x 2 x 2 factorial design: (400 mcg/d folicacid + 100 mcg/d vitamin B(12) v. placebo)x(physical activity v. nutrition promotion control)x(mental health literacy v. pain information control). The initial target sample size was 2000; however, only 909 adults (60-74 years) met the study criteria. Interventions were delivered by mail with telephone calls. The main outcome was depressive symptoms on the Patient Health Questionnaire (PHQ-9) at 6 weeks, 6, 12 and 24 months
Meta-analysis of folicacid supplementation trials on risk of cardiovascular disease and risk interaction with baseline homocysteine levels Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Meta-analysis: folicacid in the chemoprevention of colorectal adenomas and colorectal cancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Folicacid to reduce neonatal mortality from neural tube disorders Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Effects of homocysteine-lowering with folicacid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. Blood homocysteine levels are positively associated with cardiovascular disease, but it is uncertain whether the association is causal.To assess the effects of reducing homocysteine levels with folicacid and vitamin B(12) on vascular and nonvascular outcomes.Double-blind randomized controlled trial of 12,064 survivors (...) of myocardial infarction in secondary care hospitals in the United Kingdom between 1998 and 2008.2 mg folicacid plus 1 mg vitamin B(12) daily vs matching placebo.First major vascular event, defined as major coronary event (coronary death, myocardial infarction, or coronary revascularization), fatal or nonfatal stroke, or noncoronary revascularization.Allocation to the study vitamins reduced homocysteine by a mean of 3.8 micromol/L (28%). During 6.7 years of follow-up, major vascular events occurred in 1537
Efficacy of homocysteine-lowering therapy with folicacid in stroke prevention: a meta-analysis Efficacy of homocysteine-lowering therapy with folicacid in stroke prevention: a meta-analysis Efficacy of homocysteine-lowering therapy with folicacid in stroke prevention: a meta-analysis Lee M, Hong KS, Chang SC, Saver JL CRD summary The authors concluded that folicacid supplementation was not associated with a major effect in averting stroke. This conclusion reflects the evidence presented (...) and is likely to be reliable, although incomplete reporting of review processes suggests a need for some caution. Authors' objectives To assess the efficacy of folicacid supplementation in the prevention of stroke. Searching MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL) and ClinicalTrials.gov were searched from January 1966 to May 2009. Search terms were reported. No language restrictions were applied. Abstracts of American Heart Association-sponsored meetings were searched from January
Management issues for women with epilepsy--focus on pregnancy (an evidence-based review): III. Vitamin K, folicacid, blood levels, and breast-feeding A committee assembled by the American Academy of Neurology (AAN) reassessed the evidence related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folicacid and prenatal vitamin K use and the clinical implications of placental and breast-milk transfer of antiepileptic drugs (AEDs). The committee evaluated (...) the available evidence based on a structured literature review and classification of relevant articles. Preconceptional folicacid supplementation is possibly effective in preventing major congenital malformations in the newborns of WWE taking AEDs. There is inadequate evidence to determine if the newborns of WWE taking AEDs have a substantially increased risk of hemorrhagic complications. Primidone and levetiracetam probably transfer into breast milk in clinically important amounts. Valproate
Prevalence of severe congenital heart disease after folicacid fortification of grain products: time trend analysis in Quebec, Canada. To investigate whether the 1998 government policy for mandatory fortification of flour and pasta products with folate was followed by a reduction in the prevalence of severe congenital heart defects.Time trend analysis.Province of Quebec, Canada.Infants born in 1990-2005 identified with severe congenital heart defects (tetralogy of Fallot, endocardial cushion (...) 2083 infants born with severe congenital heart defects, corresponding to an average birth prevalence of 1.57/1000 births. Time trend analysis showed no change in the birth prevalence of severe birth defects in the nine years before fortification (rate ratio 1.01, 95% confidence interval 0.99 to 1.03), while in the seven years after fortification there was a significant 6% decrease per year (0.94, 0.90 to 0.97).Public health measures to increase folicacid intake were followed by a decrease
Folicacid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement. In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that all women planning or capable of pregnancy take a multivitamin supplement containing folicacid for the prevention of neural tube defects. This recommendation is an update of the 1996 USPSTF recommendation.The USPSTF reviewed the evidence on folicacid supplementation in women of childbearing age published (...) since the 1996 USPSTF recommendation. The USPSTF did not review the evidence on folicacid food fortification, counseling to increase dietary intake, or screening for neural tube defects.The USPSTF recommends that all women planning or capable of pregnancy take a daily supplement containing 0.4 to 0.8 mg (400 to 800 microg) of folicacid. (Grade A recommendation).
Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Neural tube defects (NTDs) are among the most common birth defects in the United States. In 1996, the U.S. Preventive Services Task Force (USPSTF) recommended that all women planning a pregnancy or capable of conception take a supplement containing folicacid to reduce the risk for NTDs.To search for new evidence published since 1996 on the benefits (...) and harms of folicacid supplementation for women of childbearing age to prevent neural tube defects in offspring, to inform an updated USPSTF recommendation.MEDLINE and Cochrane Central Register of Controlled Trials searches from January 1995 through December 2008, recent systematic reviews, reference lists of retrieved articles, and expert suggestions.English-language randomized, controlled trials; cohort studies; case-control studies; systematic reviews; and meta-analyses were selected
Practice Parameter update: Managment issues for women with epilepsy - Focus on pregnancy: Vitamin K, folicacid, blood levels, and breastfeeding DOI 10.1212/WNL.0b013e3181a6b325 2009;73;142-149 Published Online before print April 27, 2009 Neurology C. L. Harden, P. B. Pennell, B. S. Koppel, et al. of Neurology and American Epilepsy Society Technology Assessment Subcommittee of the American Academy the Quality Standards Subcommittee and Therapeutics and Vitamin K, folicacid, blood levels (...) , MD J. Hopp, MD T.Y. Ting, MD W.A. Hauser, MD D.Thurman,MD,MPH P.W.Kaplan,MB,FRCP J.N. Robinson, MD J.A. French, MD S. Wiebe, MD A.N. Wilner, MD B. Vazquez, MD L. Holmes, MD A. Krumholz, MD R. Finnell, PhD P.O. Shafer, RN, MN C. Le Guen ABSTRACT Objective:To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folicacid use, prenatal vitamin K use, risk of hemorrhagic disease of the newborn, clinical implications
Management issues for women with epilepsy-focus on pregnancy: vitamin k, folicacid, blood levels, and breastfeeding Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folicacid, blood levels, and breastfeeding | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share July 14, 2009 ; 73 (2) Special (...) Article Practice Parameter update: Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): Vitamin K, folicacid, blood levels, and breastfeeding Report of the Quality Standards Subcommittee and Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and American Epilepsy Society C. L. Harden , P. B. Pennell , B. S. Koppel , C. A. Hovinga , B. Gidal , K. J. Meador , J. Hopp , T. Y. Ting , W. A. Hauser , D. Thurman , P. W. Kaplan , J. N
Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force Wolff T, Witkop CT, Miller T, Syed SB Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Wolff T, Witkop CT, Miller T, Syed SB. Folicacid supplementation for the prevention of neural tube defects: an update of the evidence for the U.S. Preventive Services Task Force. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Synthesis No 70. 2009 Authors' objectives To update the evidence on folicacid